These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 29572258)

  • 1. Direct Imaging of Drug Distribution and Target Engagement of the PARP Inhibitor Rucaparib.
    Kossatz S; Carney B; Farley C; Weber WA; Drain CM; Reiner T
    J Nucl Med; 2018 Aug; 59(8):1316-1320. PubMed ID: 29572258
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of
    Liao M; Jaw-Tsai S; Beltman J; Simmons AD; Harding TC; Xiao JJ
    Xenobiotica; 2020 Sep; 50(9):1032-1042. PubMed ID: 32129697
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Poly(ADP-ribose) Polymerase in Neurodegeneration: Radiosynthesis and Radioligand Binding in ARC-SWE tg Mice.
    Alluri SR; Riss PJ
    ACS Chem Neurosci; 2018 Jun; 9(6):1259-1263. PubMed ID: 29544053
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel pharmacological effects of poly (ADP-ribose) polymerase inhibitor rucaparib on the lactate dehydrogenase pathway.
    Nonomiya Y; Noguchi K; Katayama K; Sugimoto Y
    Biochem Biophys Res Commun; 2019 Mar; 510(4):501-507. PubMed ID: 30737031
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PARP activity in peripheral blood lymphocytes as a predictive biomarker for PARP inhibition in tumor tissues - A population pharmacokinetic/pharmacodynamic analysis of rucaparib.
    Wang DD; Li C; Sun W; Zhang S; Shalinsky DR; Kern KA; Curtin NJ; Sam WJ; Kirkpatrick TR; Plummer R
    Clin Pharmacol Drug Dev; 2015 Mar; 4(2):89-98. PubMed ID: 27128213
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PARP inhibitor rucaparib induces changes in NAD levels in cells and liver tissues as assessed by MRS.
    Almeida GS; Bawn CM; Galler M; Wilson I; Thomas HD; Kyle S; Curtin NJ; Newell DR; Maxwell RJ
    NMR Biomed; 2017 Sep; 30(9):. PubMed ID: 28543772
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumour cell retention of rucaparib, sustained PARP inhibition and efficacy of weekly as well as daily schedules.
    Murray J; Thomas H; Berry P; Kyle S; Patterson M; Jones C; Los G; Hostomsky Z; Plummer ER; Boddy AV; Curtin NJ
    Br J Cancer; 2014 Apr; 110(8):1977-84. PubMed ID: 24556618
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vasoactivity of rucaparib, a PARP-1 inhibitor, is a complex process that involves myosin light chain kinase, P2 receptors, and PARP itself.
    McCrudden CM; O'Rourke MG; Cherry KE; Yuen HF; O'Rourke D; Babur M; Telfer BA; Thomas HD; Keane P; Nambirajan T; Hagan C; O'Sullivan JM; Shaw C; Williams KJ; Curtin NJ; Hirst DG; Robson T
    PLoS One; 2015; 10(2):e0118187. PubMed ID: 25689628
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Imaging PARP with [
    Chan CY; Chen Z; Destro G; Veal M; Lau D; O'Neill E; Dias G; Mosley M; Kersemans V; Guibbal F; Gouverneur V; Cornelissen B
    Eur J Nucl Med Mol Imaging; 2022 Sep; 49(11):3668-3678. PubMed ID: 35614267
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structural Basis for Potency and Promiscuity in Poly(ADP-ribose) Polymerase (PARP) and Tankyrase Inhibitors.
    Thorsell AG; Ekblad T; Karlberg T; Löw M; Pinto AF; Trésaugues L; Moche M; Cohen MS; Schüler H
    J Med Chem; 2017 Feb; 60(4):1262-1271. PubMed ID: 28001384
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors.
    Du Y; Yamaguchi H; Wei Y; Hsu JL; Wang HL; Hsu YH; Lin WC; Yu WH; Leonard PG; Lee GR; Chen MK; Nakai K; Hsu MC; Chen CT; Sun Y; Wu Y; Chang WC; Huang WC; Liu CL; Chang YC; Chen CH; Park M; Jones P; Hortobagyi GN; Hung MC
    Nat Med; 2016 Feb; 22(2):194-201. PubMed ID: 26779812
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sensitization of colorectal cancer to irinotecan therapy by PARP inhibitor rucaparib.
    Augustine T; Maitra R; Zhang J; Nayak J; Goel S
    Invest New Drugs; 2019 Oct; 37(5):948-960. PubMed ID: 30612311
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of differential biological activity and synergy between the PARP inhibitor rucaparib and its major metabolite.
    Hu H; Serra C; Zhang W; Scrivo A; Fernández-Carasa I; Consiglio A; Aytes A; Pujana MA; Llebaria A; Antolin AA
    Cell Chem Biol; 2024 May; 31(5):973-988.e4. PubMed ID: 38335967
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rucaparib: An emerging parp inhibitor for treatment of recurrent ovarian cancer.
    Musella A; Bardhi E; Marchetti C; Vertechy L; Santangelo G; Sassu C; Tomao F; Rech F; D'Amelio R; Monti M; Palaia I; Muzii L; Benedetti Panici P
    Cancer Treat Rev; 2018 May; 66():7-14. PubMed ID: 29605737
    [TBL] [Abstract][Full Text] [Related]  

  • 15. How safe is rucaparib in ovarian cancer?
    Cosgrove CM; O'Malley DM
    Expert Opin Drug Saf; 2018 Dec; 17(12):1249-1255. PubMed ID: 30449210
    [No Abstract]   [Full Text] [Related]  

  • 16. PARP inhibitor cyanine dye conjugate with enhanced cytotoxic and antiproliferative activity in patient derived glioblastoma cell lines.
    Choi PJ; Cooper E; Schweder P; Mee E; Turner C; Faull R; Denny WA; Dragunow M; Park TI; Jose J
    Bioorg Med Chem Lett; 2020 Jul; 30(14):127252. PubMed ID: 32527552
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Poly (ADP-ribose) polymerase inhibition enhances trastuzumab antitumour activity in HER2 overexpressing breast cancer.
    García-Parra J; Dalmases A; Morancho B; Arpí O; Menendez S; Sabbaghi M; Zazo S; Chamizo C; Madoz J; Eroles P; Servitja S; Tusquets I; Yelamos J; Lluch A; Arribas J; Rojo F; Rovira A; Albanell J
    Eur J Cancer; 2014 Oct; 50(15):2725-34. PubMed ID: 25128455
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Strategies Employed for the Development of PARP Inhibitors.
    Canan S; Maegley K; Curtin NJ
    Methods Mol Biol; 2017; 1608():271-297. PubMed ID: 28695516
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rucaparib antagonize multidrug resistance in cervical cancer cells through blocking the function of ABC transporters.
    Chen Z; Ling K; Zhu Y; Deng L; Li Y; Liang Z
    Gene; 2020 Oct; 759():145000. PubMed ID: 32717310
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Attenuation of Tumor Burden in Response to Rucaparib in Lung Adenocarcinoma: The Contribution of Oxidative Stress, Apoptosis, and DNA Damage.
    Pérez-Peiró M; Valentí-Serra P; León-González B; Ampurdanés C; Duran X; Yélamos J; Barreiro E
    Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768904
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.